Increased expression of p63 and survivin in cholesteatomas

References

• Min WS, Jung HS, Park JY, Jun BH, Song GY. Immunohistochemical study on the expression of proliferative markers of the squamous epithelium of the cholesteatoma. Korean J Otolaryngol 1995; 38: 1884–92
   Google Scholar
• Sheikholeslam-Zadeh R, Decaestecker C, Delbrouck C, Danguy A, Salmon I, Zick Y, et al. The levels of expression of galectin-3, but not of galectin-1 and galectin-8, correlate with apoptosis in human cholesteatomas. Laryngoscope 2001; 111: 1042–7
   PubMed Web of Science ®Google Scholar
• Huisman MA, De Heer E, Grote JJ. Cholesteatoma epithelium is characterized by increased expression of Ki-67, p53 and p21, with minimal apoptosis. Acta Otolaryngol 2003; 123: 377–82
   PubMed Web of Science ®Google Scholar
• Albino AP, Reed JA, Bogdany JK, Sassoon J, Desloge RB, Parisier SC. Expression of p53 protein in human middle ear cholesteatomas: pathogenetic implications. Am J Otol 1998; 19: 30–6
   PubMedGoogle Scholar
• Choufani G, Mahillon V, Decaestecker C, Lequeux T, Danguy A, Salmon I, et al. Determination of the levels of expression of sarcolectin and calcyclin and of the percentages of apoptotic but not proliferating cells to enable distinction between recurrent and nonrecurrent cholesteatomas. Laryngoscope 1999; 109: 1825–31
   PubMed Web of Science ®Google Scholar
• Reis-Filho JS, Torio B, Albergaria A, Schmitt FC. p63 expression in normal skin and usual cutaneous carcinomas. J Cutan Pathol 2002; 29: 517–23
   PubMedGoogle Scholar
• Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, et al. p63, a p53 homolog at 3q27, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998; 2: 305–16
   PubMed Web of Science ®Google Scholar
• Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 2000; 157: 1769–75
   PubMed Web of Science ®Google Scholar
• Barbareschi M, Pecciarini L, Cangi MG, Macri E, Rizzo A, Viale G, et al. p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol 2001; 25: 1054–60
   PubMed Web of Science ®Google Scholar
• Quade BJ, Yang A, Wang Y, Sun D, Park J, Sheets EE, et al. Expression of the p53 homologue p63 in early cervical neoplasia. Gynecol Oncol 2001; 80: 24–9
   PubMed Web of Science ®Google Scholar
• Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999; 398: 714–18
   PubMed Web of Science ®Google Scholar
• Chiodino C, Cesinaro AM, Ottani D, Fantini F, Giannetti A, Trentini GP, et al. Expression of the novel inhibitor of apoptosis survivin in normal and neoplastic skin. J Invest Dermatol 1999; 113: 415–18
   PubMed Web of Science ®Google Scholar
• Ambrosini G, Adida C, Altieri DC. A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917–21
   PubMed Web of Science ®Google Scholar
• Yang A, McKeon F. p63 and p73: p53 mimics, menaes, and more. Nat Rev Mol Cell Biol 2000; 1: 199–207
   PubMed Web of Science ®Google Scholar
• Tsujita-Kyutoku M, Kiuchi K, Danbara N, Yuri T, Senzaki H, Tsubura A. p63 expression in normal human epidermis and epidermal appendages and their tumors. J Cutan Pathol 2003; 30: 11–17
   PubMedGoogle Scholar
• Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A, et al. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999; 398: 708–13
   PubMed Web of Science ®Google Scholar
• O'Connor DS, Grossman D, Plescia J, Li F, Zhang H, Villa A, et al. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci U S A 2000; 97: 13103–7
   PubMed Web of Science ®Google Scholar
• Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396: 580–4
   PubMed Web of Science ®Google Scholar
• Choufani G, Ghanooni R, Decaestecker C, Delbrouck K, Simon P, Schuring MP, et al. Detection of macrophage migration inhibitory factor (MIF) in human cholesteatomas and functional implications of correlations to recurrence status and to expression of matrix metalloproteinases-3/9, retinoic acid receptor-β, and anti-apoptotic galectin-3. Laryngoscope 2001; 111: 1656–62
   PubMed Web of Science ®Google Scholar
• Kojima H, Miyazaki H, Shiwa M, Tanaka Y, Moriyama H. Molecular biological diagnosis of congenital and acquired cholesteatoma on the basis of differences in telomere length. Laryngoscope 2001; 111: 867–73
   PubMed Web of Science ®Google Scholar